VEGFA and metastatic melanoma: Focusing on the aspect of immunosuppression in upregulated beta‐adrenergic signalling, we investigated predictive markers in patients with metastatic melanoma who received bevacizumab monotherapy, a specific VEGF‐A binding antibody.